Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Cash & Current Investments (2019 - 2025)

IDEAYA Biosciences' Cash & Current Investments history spans 7 years, with the latest figure at $639.4 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 5.46% year-over-year to $639.4 million; the TTM value through Dec 2025 reached $639.4 million, down 5.46%, while the annual FY2025 figure was $639.4 million, 5.46% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $639.4 million at IDEAYA Biosciences, up from $298.9 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $701.7 million in Q2 2024 and bottomed at $102.8 million in Q2 2023.
  • The 5-year median for Cash & Current Investments is $300.6 million (2021), against an average of $343.3 million.
  • The largest annual shift saw Cash & Current Investments soared 582.26% in 2024 before it crashed 83.66% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $246.8 million in 2021, then soared by 47.84% to $364.8 million in 2022, then skyrocketed by 43.93% to $525.1 million in 2023, then increased by 28.79% to $676.3 million in 2024, then dropped by 5.46% to $639.4 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Cash & Current Investments are $639.4 million (Q4 2025), $298.9 million (Q3 2025), and $114.6 million (Q2 2025).